Ronnie Andrews joined Oncocyte as Chief Executive Officer in July 2019. Before joining Oncocyte, Ronnie was the founder and principal of the Bethesda Group LLC; a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms into the marketplace.
Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. In this role, Ronnie oversaw the integration of Life Technologies’ genetic platforms, including Life’s chip-based Next Generation Sequencing Technology, Ion Torrent.
Before this, Ronnie held several other high-profile executive roles, including President of the Medical Sciences Venture within the Life Technologies Corporation, and he served as Chief Executive Officer of Clarient, a public company on the NASDAQ, which was sold to General Electric Healthcare in December 2010.
Ronnie is a passionate ambassador for the need for democratization of information into community-based environments to better manage deadly diseases like cancer, as well as control healthcare costs by keeping the patient and treatment close to home. He regularly speaks to industry groups and was selected as the Regional Winner for Ernst & Young’s Entrepreneur of the Year in 2011.
Mitch Levine joined Oncocyte as Chief Financial Officer in November 2017. Before joining Oncocyte, Mr. Levine was the Managing Partner of Kirby Cove Capital Advisors, which provides consulting services to international life sciences investment funds regarding collaboration and investment in US-based life sciences companies.
In 2002, Mr. Levine founded Enable Capital Management and grew the firm into one of the largest and most respected brands globally in alternative finance. Its flagship fund, Enable Growth Partners, provided growth capital to more than 500 private and publicly traded companies, catalyzing transformative corporate innovation, job growth, and economic expansion in technology, life sciences, consumer products, and energy.
Before founding Enable, Mr. Levine was a founding member of The Shemano Group, a leading San Francisco-based investment bank that focused on the capital needs of growth companies.
He has also worked at Bear Stearns and Lehman Brothers. Mr. Levine received his BA from the University of California, Davis.
Padma Sundar has extensive experience in launching oncology tests for global diagnostics companies, helping them achieve market leadership positions.
Before joining Oncocyte, Ms. Sundar served as Vice President of Strategy and Market Access at CellMax Life, where she launched the first blood test for preventative colon cancer screening. Before CellMax, she was a Director of Marketing at Guardant Health, where she drove a 75% increase in test volume and adoption by U.S. oncologists.
As a Senior Director at Roche Sequencing, she launched the first next-generation sequencing (NGS) liquid biopsy kit for cancer recurrence monitoring. She was also Senior Director for the oncology portfolio at Affymetrix, where she brought the first whole-genome microarray kits “OncoScan” and “CytoScan” for solid and liquid tumor profiling to 50 leading academic and reference labs worldwide.
Ms. Sundar began her career at McKinsey and Company. She received her M.B.A. and M.P.H. from the University of California, Berkeley, and her B.A. in Chemistry from the University of Delhi.
Prior to joining Oncocyte, Dr. Doug Ross was a founding principal in the Bethesda Group, LLC, a boutique consulting firm that provided technical, commercial and operational expertise to the diagnostic and pharma industry. He is an experienced medical diagnostics R&D executive with a background in research and development at the intersections between genomics, proteomics and diagnostics. He co-founded a successful genomics-based diagnostic business, served in executive leadership positions in CLIA reference laboratories, and managed proprietary content through research, development and launch.
Doug’s private sector career started in 2000 as Chief Scientific Officer of Applied Genomics, Inc. (AGI), a company he co-founded coming out of post-doctoral training at Stanford University. AGI translated insights from gene expression patterns into immunohistochemistry multivariate assays targeted to actionable clinical problems.
In 2009, Clarient, Inc., a leading national pathology reference laboratory, acquired AGI. Doug continued his role as Chief Scientific Officer and launched two proprietary products. General Electric Healthcare acquired Clarient in December 2010, and Doug continued as CSO and worked closely with the business development and partnership teams at Clarient and capital teams at GE Healthcare.
In 2011 Doug joined the Medical Science Division of Life Technologies as CSO on a consulting basis until the acquisition of Life Tech by Thermo Fisher Scientific in 2013. He was CSO of CardioDx, Inc. from April to December of 2014. In September 2015, Doug became a founding principal in Bethesda Group, LLC.
Doug obtained his M.D. and his Ph.D. in Pathology from the University of Washington while studying at the Fred Hutchinson Cancer Research Center in Seattle, WA. He completed two years of Clinical Pathology training including serving as Chief Resident at the University of California at San Francisco before joining the genomics project as a post-doc with Patrick Brown at Stanford University in 1996.
Doug Ross, M.D., Ph.D.
Chief Scientific Officer
View more >>